July 2017

Dear Colleague,

Welcome to the July 2017 edition of our newsletter, Updates on Myeloproliferative Neoplasms. This edition provides articles on such topics as evaluation for CML in the setting of unexplained leukocytosis and thrombocytosis in MPNs, risks and benefits of antithrombotic therapy in essential thrombocythemia, and administration of direct oral anticoagulants in patients with myeloproliferative neoplasms.    

This month I'd like to highlight Chapter 2 of the expert video roundtable I moderated, as it discusses the most common BCR/ABL-negative MPNs.

Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at at any time.

Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.


Lindsey Lyle, MS, PA-C

Instructor, Medicine-Hematology

University of Colorado, Anschutz Medical Campus


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.